EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma

Praveen Kumar Tiwari, Bomin Ku, Drew A Harrison, Sarah Rizvi, Samuel Ojeda, Jessica Duffy, Leonie Cluse, Jennifer R Devlin, Nenad Bartonicek, Olga Motorna, Ann-Sophie Koglin, Barbara Karakyriakou und 21 weitere

Cell Reports · 2026

DOI: 10.1016/j.celrep.2026.117464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026. Verfasst von Praveen Kumar Tiwari und 32 weiteren Autor:innen. Beteiligte Einrichtung: Krantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA 02129, USA; Department of Medicine, Harvard Medical School,…. Hauptthemen laut MEDLINE: Multiple Myeloma, p300-CBP Transcription Factors, E1A-Associated p300 Protein. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The enhancer lysine acetyltransferases CBP/p300 are compelling targets for multiple myeloma therapy. Chemical inhibition of these multidomain factors, either through the bromodomain or the catalytic acetyltransferase domain, show promising activity in pre-clinical models. Chemical degradation is the only modality that can completely disrupt all functional domains. Our previous attempts to induce CBP/p300 targeted degradation led to a potent tool compound, dCBP-1. Here we comprehensively demonstrate across a large panel of cell lines how CBP/p300 degradation compares to inhibition, with pronounced selective antiproliferative activity toward multiple myeloma. We use chemical linker optimization strategies to create a compound with better pharmacokinetic properties. Through these we define an advanced analog of dCBP-1, dCBP-30, that has improved potency and improved in vivo properties including oral bioavailability. dCBP-30 led to potent and sustained loss of CBP and p300, potent inhibition of several myeloma-specific dependency programs, and elicits tumor reduction in xenograft models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Myelomap300-CBP Transcription FactorsE1A-Associated p300 ProteinHumansAnimalsCell Line, TumorAdministration, OralMiceXenograft Model Antitumor AssaysCell ProliferationProteolysisProteolysis Targeting ChimeraFemale

Stichwörter der Autor:innen

CBPCP: cancerCP: genomicsKATdegraderenhancerhistone acetyltransferaselysine acetyltransferasemultiple myelomanear-linkerless PROTACp300

Substanzen

p300-CBP Transcription FactorsE1A-Associated p300 ProteinEP300 protein, humanProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Krantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA 02129, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Krantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA 02129, USA.
  • Peter MacCallum Cancer Center, Laboratory Research Division, Parkville, VIC 3052, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3052, Australia.
  • Krantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA 02129, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Electronic address: christopher.ott@mgh.harvar…

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health
  • Blood Cancer United
  • National Institutes of Health National Cancer Institute
  • Worldwide Cancer Research
  • National Health and Medical Research Council
  • Paula and Rodger Riney Foundation

Zitieren

APA

Tiwari, P. K., Ku, B., Harrison, D. A., Rizvi, S., Ojeda, S., Duffy, J., Cluse, L., Devlin, J. R., Bartonicek, N., Motorna, O., Koglin, A. S., Karakyriakou, B., Gagnon, K., Iyer, R. S., Egan, R., Greninger, P., Benz, L., Greco, C., Norton, J., …, & Ott, C. J. (2026). An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell Reports. https://doi.org/10.1016/j.celrep.2026.117464

Vancouver

Tiwari PK, Ku B, Harrison DA, Rizvi S, Ojeda S, Duffy J, et al. An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell Reports. 2026. doi:10.1016/j.celrep.2026.117464

BibTeX
@article{Tiwari2026,
  author = {Tiwari, Praveen Kumar and Ku, Bomin and Harrison, Drew A and Rizvi, Sarah and Ojeda, Samuel and Duffy, Jessica and Cluse, Leonie and Devlin, Jennifer R and Bartonicek, Nenad and Motorna, Olga and Koglin, Ann-Sophie and Karakyriakou, Barbara and Gagnon, Kaitlyn and Iyer, Ramya S and Egan, Regina and Greninger, Pat and Benz, Lauren and Greco, Caroline and Norton, Julia and Kumar, Amruth and Zaniewski, Eric F and Hajizadeh, Soroush and Morris, Robert and Mullen, Genna and Kawale, Ajinkya S and Min, Sangwon and Doda, Sai Reddy and Vannam, Raghu and Zou, Lee and Haas, Wilhelm and Louissaint, Abner and Johnstone, Ricky W and Ott, Christopher J},
  title = {An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma},
  journal = {Cell Reports},
  year = {2026},
  doi = {10.1016/j.celrep.2026.117464}
}
Kostenlos starten →